205 related articles for article (PubMed ID: 34118026)
21. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
22. Genetic testing for the clinician in prostate cancer.
López-Campos F; Linares-Espinós E; Maldonado Pijoan X; Sancho Pardo G; Morgan TM; Martínez-Ballesteros C; Martínez-Salamanca J; Couñago F
Expert Rev Mol Diagn; 2020 Sep; 20(9):933-946. PubMed ID: 32885704
[TBL] [Abstract][Full Text] [Related]
23. Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients.
Wei Y; Wu J; Gu W; Qin X; Dai B; Lin G; Gan H; Freedland SJ; Zhu Y; Ye D
Eur Urol; 2019 Sep; 76(3):280-283. PubMed ID: 31248605
[TBL] [Abstract][Full Text] [Related]
24. G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis.
Huang H; Cai B
Tumour Biol; 2014 Feb; 35(2):1177-82. PubMed ID: 24026887
[TBL] [Abstract][Full Text] [Related]
25. Familial prostate cancer.
Giri VN; Beebe-Dimmer JL
Semin Oncol; 2016 Oct; 43(5):560-565. PubMed ID: 27899188
[TBL] [Abstract][Full Text] [Related]
26. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
[TBL] [Abstract][Full Text] [Related]
27. A personalised approach to prostate cancer screening based on genotyping of risk founder alleles.
Cybulski C; Wokołorczyk D; Kluźniak W; Kashyap A; Gołąb A; Słojewski M; Sikorski A; Puszyński M; Soczawa M; Borkowski T; Borkowski A; Antczak A; Przybyła J; Sosnowski M; Małkiewicz B; Zdrojowy R; Domagała P; Piotrowski K; Menkiszak J; Krzystolik K; Gronwald J; Jakubowska A; Górski B; Dębniak T; Masojć B; Huzarski T; Muir KR; Lophatananon A; Lubiński J; Narod SA;
Br J Cancer; 2013 Jun; 108(12):2601-9. PubMed ID: 23722471
[TBL] [Abstract][Full Text] [Related]
28. Practical Methods for Integrating Genetic Testing Into Clinical Practice for Advanced Prostate Cancer.
Cheng H; Powers J; Schaffer K; Sartor O
Am Soc Clin Oncol Educ Book; 2018 May; 38():372-381. PubMed ID: 30231311
[TBL] [Abstract][Full Text] [Related]
29. Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.
Szymaniak BM; Facchini LA; Giri VN; Antonarakis ES; Beer TM; Carlo MI; Danila DC; Dhawan M; George D; Graff JN; Gupta S; Heath E; Higano CS; Liu G; Molina AM; Paller CJ; Patnaik A; Petrylak DP; Reichert Z; Rettig MB; Ryan CJ; Taplin ME; Vinson J; Whang YE; Morgans AK; Cheng HH; McKay RR
JCO Oncol Pract; 2020 Dec; 16(12):811-819. PubMed ID: 32986533
[TBL] [Abstract][Full Text] [Related]
30. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
[TBL] [Abstract][Full Text] [Related]
31. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.
Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
[TBL] [Abstract][Full Text] [Related]
32. Genetic testing in prostate cancer management: Considerations informing primary care.
Giri VN; Morgan TM; Morris DS; Berchuck JE; Hyatt C; Taplin ME
CA Cancer J Clin; 2022 Jul; 72(4):360-371. PubMed ID: 35201622
[TBL] [Abstract][Full Text] [Related]
33. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
[TBL] [Abstract][Full Text] [Related]
34. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
35. Prostate Cancer Screening in a New Era of Genetics.
Cheng HH; Pritchard CC; Montgomery B; Lin DW; Nelson PS
Clin Genitourin Cancer; 2017 Dec; 15(6):625-628. PubMed ID: 28697982
[TBL] [Abstract][Full Text] [Related]
36. What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing.
Greenberg S; Slager S; Neil BO; Cooney K; Maughan B; Stopa N; Venne V; Zickmund S; Colonna S
Prostate; 2020 Apr; 80(5):441-450. PubMed ID: 32027768
[TBL] [Abstract][Full Text] [Related]
37. Germline genetics in localized prostate cancer.
Ryan ST; Nguyen V; Bree KK; Holst DD; Kader AK
Curr Opin Urol; 2019 Jul; 29(4):326-333. PubMed ID: 31116139
[TBL] [Abstract][Full Text] [Related]
38. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
39. A new paradigm of genetic testing for hereditary breast/ovarian cancers.
Kwong A; Chen JW; Shin VY
Hong Kong Med J; 2016 Apr; 22(2):171-7. PubMed ID: 26980575
[TBL] [Abstract][Full Text] [Related]
40. Germline Testing for Prostate Cancer Prognosis: Implications for Active Surveillance.
Helfand BT; Xu J
Urol Clin North Am; 2021 Aug; 48(3):401-409. PubMed ID: 34210494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
